{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:35:03Z","timestamp":1780619703149,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C26303\/A14139"],"award-info":[{"award-number":["C26303\/A14139"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41375-024-02162-5","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T07:02:28Z","timestamp":1708930948000},"page":"822-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstr\u0151m macroglobulinaemia"],"prefix":"10.1038","volume":"38","author":[{"given":"Ruth","family":"de Tute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9192","authenticated-orcid":false,"given":"Nicholas","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Clifton-Hadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilyana","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-7659","authenticated-orcid":false,"given":"Rebecca","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"2162_CR1","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","volume":"29","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, et al. Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv41\u201350.","journal-title":"Ann Oncol"},{"key":"2162_CR2","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D\u2019Sa S, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol. 2020;7:e827\u201337.","journal-title":"Lancet Haematol"},{"key":"2162_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.18036","volume":"197","author":"G Pratt","year":"2022","unstructured":"Pratt G, El-Sharkawi D, Kothari J, D\u2019Sa S, Auer R, McCarthy H, et al. Diagnosis and management of Waldenstr\u00f6m macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022;197:171\u201387.","journal-title":"Br J Haematol"},{"key":"2162_CR4","first-page":"268","volume":"90","author":"I Del Giudice","year":"2005","unstructured":"Del Giudice I, Matutes E, Osuji N, Parry-Jones N, Swansbury J, Catovsky D. Delayed response to fludarabine in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m\u2019s macroglobulinemia. Haematologica 2005;90:268\u201370.","journal-title":"Haematologica"},{"key":"2162_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3816\/CLM.2009.n.013","volume":"9","author":"AM Varghese","year":"2009","unstructured":"Varghese AM, Rawstron AC, Ashcroft AJ, Moreton P, Owen RG. Assessment of bone marrow response in Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:53\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"key":"2162_CR6","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","volume":"27","author":"SP Treon","year":"2009","unstructured":"Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830\u20135.","journal-title":"J Clin Oncol"},{"key":"2162_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol. 2010;85:670\u20134.","journal-title":"Am J Hematol"},{"key":"2162_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/j.1365-2141.2011.08726.x","volume":"154","author":"SP Treon","year":"2011","unstructured":"Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, et al. Attainment of complete\/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol. 2011;154:223\u20138.","journal-title":"Br J Haematol"},{"key":"2162_CR9","doi-asserted-by":"crossref","unstructured":"Varettoni M, Zibellini S, Merli M, Drandi D, Jim\u00e9nez C, Furlan D, et al. Molecular remission is an independent predictor of progression-free survival in patients with Waldenstr\u00f6m macroglobulinemia treated with chemo-immunotherapy: results from the FIL_BIOWM study. Hematol Oncol. 2023;41:574\u201377.","DOI":"10.1002\/hon.3082"},{"key":"2162_CR10","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","volume":"3","author":"M F\u00fcrstenau","year":"2019","unstructured":"F\u00fcrstenau M, De Silva N, Eichhorst B, Hallek M. Minimal residual disease assessment in CLL: ready for use in clinical routine? Hemasphere. 2019;3:e287.","journal-title":"Hemasphere"},{"key":"2162_CR11","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"2162_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. VIth International Workshop on Waldenstr\u00f6m macroglobulinaemia. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160:171\u20136.","journal-title":"Br J Haematol"},{"key":"2162_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0197-2456(00)00115-X","volume":"22","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials. 2001;22:117\u201325.","journal-title":"Control Clin Trials"},{"key":"2162_CR14","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","volume":"125","author":"B Paiva","year":"2015","unstructured":"Paiva B, Corchete LA, Vidriales MB, Garcia-Sanz R, Perez JJ, Aires-Mejia I, et al. The cellular origin and malignant transformation of Waldenstr\u00f6m macroglobulinemia. Blood. 2015;125:2370\u201380.","journal-title":"Blood"},{"key":"2162_CR15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"2162_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjh.15718","volume":"186","author":"K Laribi","year":"2019","unstructured":"Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186:146\u20139.","journal-title":"Br J Haematol"},{"key":"2162_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","volume":"27","author":"X Leleu","year":"2009","unstructured":"Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, et al. Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250\u20135.","journal-title":"J Clin Oncol"},{"key":"2162_CR18","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1200\/JCO.22.01805","volume":"41","author":"C Buske","year":"2023","unstructured":"Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahe B, et al. Bortezomib in combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) as first-line treatment of Waldenstr\u00f6m\u2019s macroglobulinaemia: results of a prospectively randomized multicenter European phase II trial. J Clin Oncol. 2023;41:2607\u201316.","journal-title":"J Clin Oncol"},{"key":"2162_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3816\/CLML.2011.n.040","volume":"11","author":"R Garc\u00eda-Sanz","year":"2011","unstructured":"Garc\u00eda-Sanz R, Ocio E, Caballero A, Magalhaes RJ, Alonso J, Lopes-Anglada L, et al. Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:168\u201371.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2162_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121:2051\u20138.","journal-title":"Blood"},{"key":"2162_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","volume":"103","author":"D Drandi","year":"2018","unstructured":"Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jim\u00e9nez C, Guerrini F, et al. Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia. Haematologica. 2018;103:1029\u201337.","journal-title":"Haematologica"},{"key":"2162_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.18502","volume":"200","author":"DF Moreno","year":"2023","unstructured":"Moreno DF, Lopez-Guerra M, Paz S, Oliver-Caldes A, Mena M-P, Correa JG, et al. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2023;200:187\u201396.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02162-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T11:04:08Z","timestamp":1712315048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02162-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2162"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02162-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3252644\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"10 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LC-H has received funding (which in part pays staff salary) to Sponsor and coordinate clinical trials. Funding has been awarded\/used in the last 2 years from Millennium pharmaceutics inc., Bristol-Myers Squibb Pharmaceuticals Ltd., Amgen GmBbH., Celgene Ltd., Merck Sharp and Dohme Ltd., Janssen-Cilag Ltd and Pfizer Ltd., SD\u2019S has received research funds from BeiGene and Janssen-Cilag Ltd. and has acted on an advisory board and received honoraria from BeiGene, Janssen-Cilag Ltd and Sanofi, WT has received honoraria and consultancy fees from Roche, Gilead and Celgene, GC has received educational grants from Novartis and Bristol-Myers Squibb, RO has received honoraria from AstraZeneca and Celgene and has acted on an advisory board and received honoraria from BeiGene and Janssen-Cilag Ltd, RA has received consultancy fees from BeiGene and Janssen-Cilag Ltd. Funding has been awarded to support a clinical trial from Janssen-Cilag Ltd. No other authors declared conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}